The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukemia

Leukemia Research

Volumn 32, Issue 11, 2008, Pages 1698-1708

  Kasper, Stefan ^a   Breitenbuecher, Frank ^a   Hoehn, Yvette ^a   Heidel, Florian ^a   Lipka, Daniel B ^a   Markova, Boyka ^a   Huber, Christoph ^a   Kindler, Thomas ^a   Fischer, Thomas ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Acute myeloid leukemia; FLT3; LS104; Targeted therapy; Tyrosine kinase inhibitor

Indexed keywords

CYTARABINE; DAUNORUBICIN; FLT3 LIGAND; LS 104; PHOSPHOPROTEIN; PHOSPHOTRANSFERASE INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DOWNSTREAM PROCESSING; DRUG UPTAKE; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKEMIA CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ACRYLONITRILE; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; BONE MARROW; CELL DIFFERENTIATION; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; CYTARABINE; DAUNORUBICIN; DRUG THERAPY, COMBINATION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICE; MIDDLE AGED; POINT MUTATION; SIGNAL TRANSDUCTION; STYRENES; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 47249087693     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.05.003     Document Type: Article

References (51)

1. O'Brien S.G., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. N Engl J Med 348 (2003) 994-1004
2. Ottmann O.G., Druker B.J., Sawyers C.L., Goldman J.M., Reiffers J., Silver R.T., et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100 (2002) 1965-1971
3. Wadleigh M., DeAngelo D.J., Griffin J.D., and Stone R.M. After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies. Blood 105 (2005) 22-30
4. Kottaridis P.D., Gale R.E., and Linch D.C. Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemia. Leuk Lymphoma 44 (2003) 905-913
5. Schnittger S., Schoch C., Dugas M., Kern W., Staib P., Wuchter C., et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 100 (2002) 59-66
6. Carow C.E., Levenstein M., Kaufmann S.H., Chen J., Amin S., Rockwell P., et al. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood 87 (1996) 1089-1096
7. Zheng R., Levis M., Piloto O., Brown P., Baldwin B.R., Gorin N.C., et al. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood 103 (2004) 267-274
8. Kottaridis P.D., Gale R.E., Frew M.E., Harrison G., Langabeer S.E., Belton A.A., et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98 (2001) 1752-1759
9. Frohling S., et al., AML Study Group Ulm. Acute myeloid leukemia. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 100 (2002) 4372-4380
10. Bienz M., Ludwig M., Leibundgut E.O., Mueller B.U., Ratschiller D., Solenthaler M., et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res 11 (2005) 1416-1424
11. O'Farrell A.M., Foran J.M., Fiedler W., Serve H., Paquette R.L., Cooper M.A., et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 9 (2003) 5465-5476
12. Stone R.M., DeAngelo D.J., Klimek V., Galinsky I., Estey E., Nimer S.D., et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 105 (2005) 54-60 [Epub September 2, 2004]
13. Smith B.D., Levis M., Beran M., Giles F., Kantarjian H., Berg K., et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103 (2004) 3669-3676
14. Knapper S., Burnett A.K., Littlewood T., Kell W.J., Agrawal S., Chopra R., et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 108 (2006) 3262-3270
15. Fiedler W., Serve H., Dohner H., Schwittay M., Ottmann O.G., O'Farrell A.M., et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105 (2005) 986-993
16. DeAngelo D.J., Stone R.M., Heaney M.L., Nimer S.D., Paquette R.L., Klisovic R.B., et al. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood 108 (2006) 3674-3681 [Epub August 10, 2006]
17. Cools J., Mentens N., Furet P., Fabbro D., Clark J.J., Griffin J.D., et al. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res 64 (2004) 6385-6389
18. Heidel F., Solem F.K., Breitenbuecher F., Lipka D.B., Kasper S., Thiede M.H., et al. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood 107 (2006) 293-300
19. Breitenbuecher F., Stauder T., Hoehn Y., Schnittger S., Kindler T., Giles F., et al. A novel molecular mechanism leading to primary resistance to FLT3-tyrosine kinase inhibitors in AML by formation of FLT3-ITD627E. Proceedings of the 11th Congress of the EHA (2006) [Abstract 0471]
20. Knapper S., Mills K.I., Gilkes A.F., Austin S.J., Walsh V., and Burnett A.K. The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. Blood 108 (2006) 3494-3503
21. Piloto O., Wright M., Brown P., Kim K.T., Levis M., and Small D. Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. Blood 109 (2007) 1643-1652
22. Siendones E., Barbarroja N., Torres L.A., Buendia P., Velasco F., Dorado G., et al. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors. Hematol Oncol 25 (2007) 30-37
23. Levis M., Pham R., Smith B.D., and Small D. In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood 104 (2004) 1145-1150
24. Heidel F., Cortes J., Rucker F.G., Aulitzky W., Letvak L., Kindler T., et al. Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib. Cancer 109 (2007) 907-914
25. Fischer T., Giles F., Paquette R., Schiller G., Ehninger G., Schiffer C., et al. Phase IB study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combination with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed patients with AML. Proceedings of the 11th Congress of the EHA (2006) [Abstract 0977]
26. Aleskog A., Höglund M., Pettersson J., Hermansson M., Larsson R., and Lindhagen E. In vitro activity of the flt3-inhibitor su5614 and standard cytotoxic agents in tumour cells from patients with wild type and mutated flt3 acute myeloid leukaemia. Leuk Res 29 (2005) 1079-1081
27. Mohi M.G., Boulton C., Gu T.L., Sternberg D.W., Neuberg D., Griffin J.D., et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci USA 101 (2004) 3130-3135
28. Grunberger T., Demin P., Rounova O., Sharfe N., Cimpean L., Dadi H., et al. Inhibition of acute lymphoblastic and myeloid leukemias by a novel kinase inhibitor. Blood 102 (2003) 4153-4158
29. Lipka D.B., Hoffmann L., Heidel F., Markova B., Blum M.C., Breitenbuecher F., et al. LS104, a non-ATP-competitive small molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells. Mol Cancer Ther 7 (2008) 1176-1184
30. Greil J., Gramatzki M., Burger R., Marschalek R., Peltner M., Trautmann U., et al. The acute lymphoblastic leukaemia cell line SEM with t(4;11) chromosomal rearrangement is biphenotypic and responsive to interleukin-7. Br J Haematol 86 (1994) 275-283
31. Stong R.C., Korsmeyer S.J., Parkin J.L., Arthur D.C., and Kersey J.H. Human acute leukemia cell line with the t(4;11) chromosomal rearrangement exhibits B lineage and monocytic characteristics. Blood 65 (1985) 21-31
32. Mizuki M., Fenski R., Halfter H., Matsumura I., Schmidt R., Muller C., et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 96 (2000) 3907-3914
33. Kindler T., Breitenbuecher F., Kasper S., Estey E., Giles F., Feldman E., et al. Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). Blood 105 (2005) 335-340
34. Kindler T., Breitenbuecher F., Marx A., Beck J., Hess G., Weinkauf B., et al. Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood 103 (2004) 3644-3654
35. Kindler T., Breitenbuecher F., Kasper S.T., Carius B., Gschaidmeier H., Huber C., et al. In BCR-ABL-positive cells STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C. Leukemia 17 (2003) 999-1009
36. Kasper S., Kindler T., Sonnenschein S., Breitenbuecher F., Böhmer F.D., Huber C., et al. Cross-inhibition of interferon-induced signals by GM-CSF through a block in STAT1 activation. J Interferon Cytokine Res 27 (2007) 947-959
37. Stone R.M. The difficult problem of acute myeloid leukemia in the older adult. CA Cancer J Clin 52 (2002) 363-371
38. Leith C.P., Kopecky K.J., Godwin J., McConnell T., Slovak M.L., Chen I.M., et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89 (1997) 3323-3329
39. Aribi A., Ravandi F., and Giles F. Novel agents in acute myeloid leukemia. Cancer J 12 (2006) 77-91 [review]
40. Stirewalt D.L., Willman C.L., and Radich J.P. Quantitative, real-time polymerase chain reactions for FLT3 internal tandem duplications are highly sensitive and specific. Leuk Res 25 (2001) 1085-1088
41. Hayakawa F., Towatari M., Kiyoi H., Tanimoto M., Kitamura T., Saito H., et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 19 (2000) 624-631
42. Spiekermann K., Bagrintseva K., Schwab R., Schmieja K., and Hiddemann W. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells. Clin Cancer Res 9 (2003) 2140-2150
43. Mizuki M., Schwable J., Steur C., Choudhary C., Agrawal S., Sargin B., et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood 101 (2003) 3164-3173
44. Deguchi K., and Gilliland D.G. Cooperativity between mutations in tyrosine kinases and in hematopoietic transcription factors in AML. Leukemia 16 (2002) 740-744
45. Sohal J., Phan V.T., Chan P.V., Davis E.M., Patel B., Kelly L.M., et al. A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. Blood 101 (2003) 3188-3197
46. von Lindern M., Schmidt U., and Beug H. Control of erythropoiesis by erythropoietin and stem cell factor: a novel role for Bruton's tyrosine kinase. Cell Cycle 3 (2004) 876-879
47. Blume-Jensen P., and Hunter T. Oncogenic kinase signalling. Nature 411 (2001) 355-365
48. Griffith J., Black J., Faerman C., Swenson L., Wynn M., Lu F., et al. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell 13 (2004) 169-178
49. Kiyoi H., Ohno R., Ueda R., Saito H., and Naoe T. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene 21 (2002) 2555-2563
50. Gumireddy K., Baker S.J., Cosenza S.C., John P., Kang A.D., Robell K.A., et al. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci USA 102 (2005) 1992-1997 [Epub January 27, 2005]
51. Gumireddy K., Baker S.J., Cosenza S.C., John P., Kang A.D., Robell K.A., et al. Proc Natl Acad Sci USA 102 April 12 (15) (2005) 5635 [erratum]